NCT03350542已完成3 期
EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 15
- 主要终点
- Target Lesion Failure Rate at 12-months
研究概览
简要总结
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) > 34 mm and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in diameter (by visual estimate).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria
- •Subject must be at least 18 years of age
- •Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
- •Subject is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for coronary artery bypass grafting (CABG)
- •Subject has either:
- •Symptomatic coronary artery disease with one of the following: stenosis ≥ 70%, abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test, or elevated biomarkers prior to the procedure
- •Documented silent ischemia based on one of the following: abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test, or elevated biomarkers prior to the procedure
- •Subject is willing to comply with all protocol-required follow-up evaluation Angiographic Inclusion Criteria (visual estimate)
- •Target lesion must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.5 mm and ≤4.0 mm
- •Target lesion length must be >34 mm and ≤44 mm (by visual estimate)
- •Target lesion must have visually estimated stenosis ≥50% and <100% with thrombolysis in Myocardial Infarction (TIMI) flow >1
- •Coronary anatomy is likely to allow delivery of a study device to the target lesion
- •The target lesion must be successfully predilated/pretreated. If a non-target lesion is treated, it should be treated first and should be deemed an angiographic success Note: Angiographic success is a mean lesion diameter stenosis < 50% (< 30% for stents) in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician, without the occurrence of prolonged chest pain or ECG changes consistent with MI.
- •Note: Successful predilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.
排除标准
- •Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI)
- •Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina
- •Subject has received an organ transplant or is on a waiting list for an organ transplant
- •Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
- •Planned PCI (including staged procedures) or CABG after the index procedure
- •Subject previously treated at any time with intravascular brachytherapy
- •Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)
- •Subject has one of the following (as assessed prior to enrollment):
- •Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months
- •Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)
- •Planned procedure that may cause non-compliance with the protocol or confound data interpretation
- •Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome
- •Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
- •Subject has a white blood cell (WBC) count < 3,000 cells/mm3
- •Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
- •Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
- •Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
- •Subject has signs or symptoms of active heart failure (i.e., New York Heart Association (NYHA) class IV) at the time of the index procedure
- •Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
- •Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
- •Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
- •Subject is a woman who is pregnant or nursing Angiographic Exclusion Criteria (visual estimate)
- •Subject has more than 1 target lesion, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure Note: Multiple focal stenoses will be considered as a single lesion if they can be completely covered with 1 study stent
- •Treatment of lesions in more than 2 major epicardial vessels Note: 1 target lesion in the target vessel and 1 non-target lesion in non-target vessel is allowed
- •Subject has unprotected left main coronary artery disease (>50% diameter stenosis)
- •Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure
- •Thrombus, or possible thrombus, present in the target vessel (by visual estimate)
- •Target lesion meets any of the following criteria:
- •Treatment of a single lesion with more than 1 stent
- •Left main location
- •Lesion is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate
- •Lesion is located within a saphenous vein graft or an arterial graft
- •Lesion will be accessed via a saphenous vein graft or arterial graft
- •Lesion with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
- •Lesion treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
- •Lesion is restenotic from a previous stent implantation or study stent would overlap with a previous stent
- •Non-target lesion meets any of the following criteria:
- •Located within the target vessel
- •Left main location
- •Lesion is located within a saphenous vein graft or an arterial graft
- •Lesion with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
- •Lesion treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
- •Requires additional unplanned stents (treatment of the non-target lesion with more than one stent is permitted as long as the stents are initially planned)
- •Treatment not deemed an angiographic success Note: Angiographic success is a mean lesion diameter stenosis < 50% (< 30% for stents) in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician, without the occurrence of prolonged chest pain or ECG changes consistent with MI.
研究组 & 干预措施
SYNERGY 48 mm
Experimental
SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
干预措施: SYNERGY 48 mm (Device)
结局指标
主要结局
Target Lesion Failure Rate at 12-months
时间窗: 12-month
The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.
次要结局
- Cardiac Death or MI Rate(12 months)
- All Death or MI Rate(12 months)
- Periprocedural Technical Success Rate(Day 1 (periprocedural))
- Target Lesion Revascularization (TLR) Rate at 12 Months(12 months)
- Target Vessel Revascularization (TVR) Rate at 12 Months.(12 months)
- Target Vessel Failure (TVF) Rate at 12 Months(12 months)
- MI (Q-wave and Non-Q-wave) Rate(12 months)
- Cardiac Death Rate(12 months)
- Non-cardiac Death Rate(12 months)
- All Death Rate(12 months)
- All Death/MI/TVR Rate(12 months)
- Stent Thrombosis Rate(12 months)
- Periprocedural Clinical Procedural Success Rate(12 months)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
不适用
Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary StentCoronary Artery DiseaseNCT01135225Boston Scientific Corporation291
招募中
不适用
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised PatientsAlpha RadiationImmunocompromisedCarcinoma, SquamousBrachytherapySquamous Cell CarcinomaSkin CancerNCT06615635Alpha Tau Medical LTD.28
招募中
3 期
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in ChildrenDiffuse Intrinsic Pontine GliomaNCT04532229Biotech Pharmaceutical Co., Ltd.48
已完成
4 期
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticitySpasticity, MuscleNCT03908580Medy-Tox120
已完成
4 期
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy PatientsTransthyretin Amyloid Polyneuropathy (ATTR-PN)NCT04828993Pfizer15